Author: Ravi Shankar

Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Sept. 24, 2026 (GLOBE NEWSWIRE) — Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the appointment of Keli Walbert to its Board of Directors, effective September 24, 2026. Ms. Walbert will join the Board’s Audit Committee, succeeding Akshay Vaishnaw, MD, PhD, who will remain a member of the Board.

“Keli’s experience turning novel scientific innovations into therapies that reach patients is exactly what Hemab needs as we work to close longstanding gaps in the treatment of bleeding disorders,” said Benny Sørensen, MD, PhD, CEO of Hemab. “As we advance our pipeline toward later-stage development, her experience building the commercial capabilities that bring new therapies to people with high-unmet-need conditions will strengthen our Board at a pivotal time for Hemab.”

“We are pleased to welcome Keli to Hemab’s Board of Directors. Her commercial expertise strengthens our Board as we work to bring new therapies to people living with serious, underserved bleeding disorders,” said John Maraganore, PhD, Chair of Hemab’s Board of Directors. “Her success launching medicines from very common to rare diseases is a good strategic match as we advance toward key milestones across the pipeline.”

Ms. Walbert brings more than 20 years of commercial leadership experience in biopharmaceuticals, spanning sales and marketing, market access, patient services, advocacy, and analytics. Her therapeutic background covers immunology, rheumatology, dermatology, gastroenterology, ophthalmology, nephrology, neurology and metabolic disease, with experience in indications of all market sizes. She most recently served as Executive Vice President, U.S. Commercial at Horizon Therapeutics, where she oversaw commercial strategy and organizational development across more than 10 marketed brands. Earlier in her career, she held leadership roles at AbbVie, the American Medical Association, Abbott and United Healthcare. Over the course of her career, she led the commercial launches of HUMIRA^®, TEPEZZA^® and DUOPA^®. She has been recognized with the Healthcare Businesswomen’s Association’s Luminary Award and an MM+M Women of Distinction Award. She earned her master’s degree from Northwestern University and bachelor’s degree from the University of Louisville.

“I’m honored to join Hemab’s Board at such a pivotal moment for the company,” said Ms. Walbert. “Hemab’s mission to bring new options to people living with serious, high-unmet-need bleeding disorders reflects the kind of impact I’ve built my career around, and I look forward to helping them move their pipeline to patients as quickly and effectively as possible.”

About Hemab Therapeutics
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease, and HMB-003, an antifibrinolytic targeting plasmin inhibition in clinical development for heavy menstrual bleeding.

Learn more at hemab.com. Follow us on LinkedIn, Facebook, Instagram, and X.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Hemab’s strategy, future operations, prospects and plans, objectives of management, and the clinical potential of sutacimig, HMB-002 and HMB-003, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Hemab may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Hemab’s ability to initiate and enroll patients in clinical trials; whether results from preclinical studies and earlier clinical trials will be predictive of the results of later clinical trials; whether Hemab’s cash resources will be sufficient to fund Hemab’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Hemab’s filings with the Securities and Exchange Commission (SEC), including Hemab’s most recent Form 10-Q and in subsequent filings Hemab may make with the SEC. In addition, the forward-looking statements included in this press release represent Hemab’s views as of the date of this press release. Hemab anticipates that subsequent events and developments will cause its views to change. However, while Hemab may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Hemab’s views as of any date subsequent to the date of this press release.

Media:
Deerfield Group
Peg Rusconi
peg.rusconi@deerfieldgroup.com

Investors:
Hemab Therapeutics
Mads Behrndt
investors@hemab.com

• Anthropic to leverage Akamai Cloud’s distributed infrastructure and software to support CPU workload growth at scale
• The transaction provides for the potential expansion of the relationship by up to an additional $9 billion, which represents a total potential commitment of approximately $20 billion
• Akamai has issued a warrant to Anthropic, the continued vesting of which is tied to the successful expansion of the relationship, for up to approximately 5% of Akamai’s common stock outstanding. A portion of the warrant representing approximately 2% of Akamai’s common stock outstanding is expected to vest in connection with today’s announced commitment

CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) — Akamai Technologies, Inc. (NASDAQ: AKAM), today announced a significantly expanded relationship with Anthropic for $11.6 billion of contractual commitment over seven years. The multi-year commitment will support Anthropic’s accelerating CPU workload demands by leveraging Akamai Cloud’s distributed AI infrastructure and software.

The deal adds to the more than $2.8 billion in multi-year Cloud Infrastructure Services (CIS) commitments across Akamai’s customer base previously announced this year. These agreements underscore a growing demand for Akamai to enable customers to build, deploy and operate AI workloads at scale.

As part of the increased strategic alignment between Akamai and Anthropic, Akamai has issued a warrant to Anthropic for the purchase of non-voting convertible Series B Preferred Stock representing 7.7 million shares of Akamai’s common stock on an as-converted basis, or up to approximately 5% of Akamai’s common stock outstanding, at an exercise price of $111.33 per share of common stock. A portion of the warrant representing approximately 2% of Akamai’s common stock outstanding is expected to vest in connection with today’s announced $11.6 billion commitment. The remaining approximately 3% would vest throughout the successful expansion of the commitment up to an additional $9 billion within the seven-year term of the warrant. Each additional $3 billion purchase of cloud services, at mutually agreed upon terms, will result in the vesting of approximately 1% of Akamai’s common stock outstanding.

“Anthropic is advancing the AI revolution and we are thrilled they chose Akamai’s capabilities for building and operating AI infrastructure at scale,” said Dr. Tom Leighton, co-founder and CEO, Akamai. “Akamai has an unparalleled reputation for helping our customers achieve their business-critical goals and build the future. Our expanding global footprint, combined with our years of experience serving the world’s largest enterprises, positions us to be the infrastructure provider for secure and responsible AI applications and workloads.”

Akamai Cloud supports a continuum of compute from core to edge, with a vastly distributed network spanning thousands of points of presence. The platform is built with diversified hardware to enable customers to build and run applications and optimize how they are served to their users and agents. Akamai’s global infrastructure enables the full lifecycle of applications in the AI era, and ensures they are fast, reliable and secure.

Total capital expenditures related to today’s $11.6 billion commitment are estimated to be approximately $5.5 billion. Akamai anticipates no impact to the company’s 2026 revenue guidance, and an increase of approximately $1.7 billion in capital expenditures in 2026 to secure and pre-purchase critical supply chain components, including memory.

The company will host a conference call today at 5:30 p.m. Eastern Time. The call can be accessed via 1-833-634-5020 (or 1-412-902-4238 for international calls) and using passcode Akamai Technologies Call. A live webcast of the call may be accessed at www.akamai.com in the Investor Relations section. In addition, a replay of the call will be available for two weeks following the conference by calling 1-855-669-9658 (or 1-412-317-0088 for international calls) and using passcode 2566572. The archived webcast of this event may be accessed through the Akamai website.

About Akamai
Akamai is the cloud company that powers and protects an AI-driven world. Our cloud platform extends high-performance cloud computing from the core to the edge, enabling organizations to build and scale next-generation AI applications while delivering comprehensive, multi-layered security to safeguard enterprises against evolving cyber threats. Learn more at akamai.com and akamai.com/blog, or follow Akamai Technologies on X and LinkedIn.

Akamai Statement Under the Private Securities Litigation Reform Act
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding future events and the future results of Akamai. All statements other than statements of historical facts are statements that could be deemed forward-looking statements. Such forward-looking statements include, but are not limited to, statements about Akamai’s capabilities, the expected benefits of the transaction to Akamai, the potential impact of the issuance of the warrant, the potential expansion of the relationship between Akamai and Anthropic and the impact of the transaction on Akamai’s financial condition and financial guidance. These statements are subject to risks and uncertainties and are based on the beliefs and assumptions of Akamai’s management as of the date hereof based on information currently available to Akamai’s management. Use of words such as “believes,” “could,” “expects,” “anticipates,” “intends,” “plans,” “seeks,” “projects,” “estimates,” “should,” “would,” “forecasts,” “if,” “continues,” “goal,” “likely,” “may,” “will,” variations of such words or similar expressions are intended to identify a forward-looking statement. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions. Actual results may differ materially from the forward-looking statements Akamai makes as a result of various factors, including, but not limited to: Akamai being unable to achieve the anticipated benefits of the transaction; Akamai’s capabilities failing to meet expectations, including due to defects, security breaches, delays in performance or other similar problems; effects of competition, including pricing pressure, data center capacity and changing business models; impact of macroeconomic trends, including economic uncertainty, turmoil in the financial services industry, the effects of inflation, rising and fluctuating interest rates, foreign currency exchange rate fluctuations, securities market volatility and monetary supply fluctuations; potential cash flow constraints and the ability to raise capital; continuing supply chain and logistics costs, constraints, changes or disruptions; defects or disruptions in Akamai’s products or IT systems, including cyber-attacks, data breaches or malware; changes to economic, political and regulatory conditions in the United States or internationally; and other factors that are discussed in the company’s most recent Annual Report on Form 10-K, subsequent quarterly reports on Form 10-Q and other documents filed with the Securities and Exchange Commission. Potential investors, stockholders and other readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. Akamai disclaims any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

Contacts:
Johanna Schmitt		Mark Stoutenberg
Media Relations		Investor Relations
Akamai Technologies		Akamai Technologies
AkamaiPR@akamai.com		mstouten@akamai.com

— Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver franchise, building on recent regulatory clearances for PM577a —

— Initial clinical data expected in 2027 —

CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for PM647, an investigational in vivo Prime Editor for Alpha-1 Antitrypsin Deficiency (AATD). The clearance enables PM647 to proceed to clinical study initially in the United States, where approximately 100,000 people carry the PiZZ genotype that PM647 is designed to correct.

“FDA clearance of the PM647 IND is an important milestone for Prime Medicine, marking continued momentum across our liver franchise,” said Allan Reine, M.D., Chief Executive Officer of Prime Medicine. “PM647 has the potential to change how AATD is treated, offering a Prime Editing-based approach that moves beyond protein replacement and targets the root cause of disease. By correcting the underlying mutation and restoring production of fully functional AAT, PM647 may simultaneously address both lung and liver manifestations of AATD and provide a differentiated, one-time treatment approach for patients. Beyond its therapeutic potential, PM647 demonstrates the repeatability and productivity of Prime Medicine’s platform. Just months after regulatory clearances for PM577a, the advancement of PM647 into clinical development also reinforces how Prime Medicine’s modular platform and universal liver LNP can support the rapid progression of multiple programs.”

Phase 1/2 Clinical Trial

The Phase 1/2 clinical trial will be a global, single-arm, open-label, first-in-human study designed to evaluate the safety, tolerability and preliminary clinical efficacy of ascending doses of a one-time intravenous infusion of PM647 in adults with AATD. The study will initially enroll adult participants with lung-only manifestations of AATD. Upon demonstration of tolerability in lung-only participants, the study will expand to include a separate cohort enrolling adults with significant liver disease, with or without concurrent lung manifestations of AATD.

About PM647

PM647 is an investigational, one-time in vivo Prime Editor designed to correct the E342K (Pi*Z) mutation in the SERPINA1 gene, the most common cause of AATD. By correcting the mutation at its source, PM647 is designed to restore production of functional M-AAT and address both the liver and lung manifestations of the disease. In fully humanized mouse models, PM647 achieved high editing efficiency and restored corrected M-AAT protein into the healthy human range at clinically relevant doses with a single infusion. PM647 uses the same liver-directed lipid nanoparticle (LNP) as PM577a, Prime Medicine’s investigational program for Wilson disease.

About Alpha-1 Antitrypsin Deficiency

Alpha-1 Antitrypsin Deficiency is an inherited genetic disorder caused by variants in the SERPINA1 gene. In people with severe disease, insufficient functional alpha-1 antitrypsin can lead to progressive lung damage, while accumulation of mutant protein in the liver can cause progressive liver disease. Patients have no approved curative treatment that addresses the underlying genetic cause of both manifestations of the disease. Approximately 200,000 people are estimated to carry the PiZZ genotype across United States and Europe.

About Prime Medicine

Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.

Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around its core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high-value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Over time, the Company intends to maximize Prime Editing’s broad and versatile therapeutic potential, as well as the modularity of the Prime Editing platform, to rapidly and efficiently expand beyond the diseases in its current pipeline, potentially including additional genetic diseases, immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.

© 2026 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Prime Medicine’s beliefs and expectations regarding: the potential of PM647 to correct the causative mutations of, and to treat, AATD; the Phase 1/2 clinical trial of PM647, including the trial design, global reach of the trial and the anticipated timing of initial clinical data in 2027; the continued development and advancement of the Company’s AATD and Wilson disease programs; the modularity of the Prime Editing platform and universal liver LNP and the benefits thereof; and the potential of Prime Editing to unlock opportunities across thousands of potential indications.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: uncertainties related to Prime Medicine’s product candidates entering clinical trials; the authorization, initiation, and conduct of preclinical and IND-enabling studies and other development requirements for potential product candidates, including uncertainties related to opening INDs and obtaining regulatory approvals; risks related to the development and optimization of new technologies, the results of preclinical studies, or clinical studies not being predictive of future results in connection with future studies; the scope of protection Prime Medicine is able to establish and maintain for intellectual property rights covering its Prime Editing technology; Prime Medicine’s ability to identify and enter into future license agreements and collaborations; Prime Medicine’s expectations regarding the anticipated timeline of its cash runway and future financial performance; and general economic, industry and market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Prime Medicine’s most recent Annual Report on Form 10-K, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Prime Medicine’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Prime Medicine explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor and Media Contacts

Gregory Dearborn
Prime Medicine
857-209-0696
gdearborn@primemedicine.com

Hannah Deresiewicz
Precision AQ
212-362-1200
hannah.deresiewicz@precisionaq.com

Long-term roadmap integrates music, education, wellness, hospitality, and residential real estate into a single destination ecosystem on Chiba’s Pacific coast

CHOSHI, CHIBA PREFECTURE, JAPAN, Sept. 24, 2026 (GLOBE NEWSWIRE) — OFA Group today outlined its long-term development vision and roadmap for a new oceanfront cultural destination in Choshi City, a multi-phase initiative designed to bring together classical music and the arts, education, wellness, hospitality, and residential real estate into one cohesive destination ecosystem on Japan’s Pacific coast.

Located at the easternmost tip of the Kanto region, Choshi is known for its rugged coastline, the historic Inubosaki Lighthouse, some of the first sunrises in mainland Japan, a working fishing port, and the local Choshi Dentetsu rail line. OFA sees the city’s natural setting and cultural heritage as the foundation for a destination that draws visitors, residents, and cultural institutions together in one place, rather than developing music, housing, and hospitality as separate, disconnected efforts.

“This is about more than any single building or event,” said Larry Wong, CEO of OFA Group. “We are working to organically link music, education, wellness, hospitality, and residential living so that Choshi’s identity as a cultural destination and OFA’s long-term investment in the city grow together, not on separate tracks. Every piece of this roadmap is designed to reinforce the others.”

Music as the cultural core. At the center of OFA’s roadmap is a renewed commitment to classical music as Choshi’s defining cultural asset. Building on lessons from its earlier festival programming, OFA is re-establishing its approach around a sustainable, brand-led business model — one that will inform how future concerts, education programs, and performance venues are developed, rather than starting from venues and working backward. OFA is in early discussions with cultural producers and organizers about multi-year programming that could begin as soon as 2028, and will share further details as those conversations progress.

A coastal home for wellness and residential living. As part of the same vision, OFA is pursuing the redevelopment of a coastal parcel in Choshi’s Tokawa area into a premium, private-pay senior living community — a short walk from Choshi Dentetsu’s Tokawa Station and the coastline. The project, currently under a provisional agreement with Choshi City and subject to City Council approval, is envisioned as a residence where wellness, hospitality-grade service, and Choshi’s emerging cultural identity come together for residents, rather than a standalone care facility. Planning work, including site design and regulatory review, is underway.

Education and hospitality as connective tissue. OFA’s roadmap also calls for education programming — tied to the destination’s music and cultural offerings — and hospitality experiences that welcome visitors to Choshi for the first time and give residents and program participants reasons to stay engaged over the long term. These components are earlier in development and will be shaped in coordination with the music and residential pillars as they mature.

OFA intends to advance this roadmap in phases over the coming years, working closely with Choshi City, local stakeholders, and prospective partners at each stage. The company will provide updates as key milestones — including municipal approvals, program partnerships, and site plans — are finalized.

About OFA Group

​​OFA Group (NASDAQ: OFAL) is a technology-driven architecture, real estate, and digital asset infrastructure company operating at the intersection of AI, construction, and blockchain. OFA is revolutionizing the architectural industry by integrating cutting-edge AI technology and an interdisciplinary approach, which improves processes for building code compliance, construction design, time management, labor efficiency, effectiveness, and overall productivity. Learn more at OFAgroup.com. 

Forward-Looking Statements 

This press release contains forward-looking statements. These forward-looking statements are not historical facts, but only predictions and generally can be identified by use of statements that include phrases such as “will,” “may,” “should,” “continue,” “anticipate,” “assume,” “believe,” “expect,” “plan,” “appear,” “project,” “estimate,” “hope,” “intend,” “target,” “forecast,” or other words or phrases of similar import. Similarly, statements that describe our objectives, plans or goals also are forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those currently anticipated. These forward-looking statements include, but are not limited to, statements regarding the expected capabilities, adoption, commercialization, market acceptance, future development, revenue opportunities, customer growth, product enhancements, and business strategy relating to the QikBIM platform. Actual results may differ materially due to various risks and uncertainties, including market acceptance of the Company’s AI technologies, customer adoption rates, competitive developments, technological challenges, regulatory changes, and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release are made only as of the date of this press release. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law. 

Media Contact 
Susan Fortner 
President, BPR International 
Susan@BPRInternational
614.562.0054 

Investor Relations
OFA Group
Email: info@ofagroup.com
Website: www.ofagroup.com

CHICAGO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Amlan^® International, the animal health business of Oil-Dri^® Corporation of America, will return to World Dairy Expo as the official Media Room sponsor. Taking place September 29–October 2 in Madison, Wisconsin, World Dairy Expo brings together dairy producers, industry professionals and media from around the world to exchange insights and explore the latest developments shaping the global dairy industry.

This year marks Amlan’s fifth consecutive year sponsoring the Media Room, reflecting the company’s continued commitment to supporting the dairy industry and advancing conversations around feed safety, animal health and productivity.

During the show, Dr. Wade Robey, President, Amlan International, will be available for media interviews to discuss evolving mycotoxin challenges facing dairy producers. In particular, Dr. Robey will share insights into rising levels of zearalenone and the potential implications for herd fertility, as well as why producers should consider the broader impact of exposure to multiple mycotoxins.

“Today’s mycotoxin challenges extend well beyond any single toxin,” said Dr. Robey. “As toxin prevalence continues to evolve, producers need to understand what may be present in their feed and how those challenges can affect herd health, reproductive performance and overall productivity.”

As part of its Media Room sponsorship, Amlan invites registered media attending World Dairy Expo to enjoy a complimentary boxed lunch on Tuesday, September 29, from 11 a.m. to 1 p.m.

“Amlan values the opportunity World Dairy Expo provides to connect with the people who are helping move the dairy industry forward,” said Reagan Culbertson, Vice President, Strategic Marketing, B2B. “Supporting the Media Room is one way we can help encourage the exchange of information and ideas while continuing important conversations around the challenges and opportunities facing dairy producers.”

Media interested in scheduling an interview with Dr. Robey during World Dairy Expo are encouraged to contact Lily Nemeroff, Marketing and Communications Manager, at lily.nemeroff@amlan.com.

For more information about Amlan International, visit www.amlan.com.

Company Information
Amlan is the animal health business of Oil-Dri Corporation of America, a leading global manufacturer and marketer of sorbent minerals. Leveraging over 80 years of expertise in mineral science, Oil-Dri Corporation of America, doing business as “Amlan International,” is a publicly traded company on the New York Stock Exchange (NYSE: ODC). Amlan International sells feed additives worldwide. Product availability may vary by country; associated claims do not constitute medical claims and may differ based on government requirements.

Contact:
Reagan Culbertson, Vice President of Strategic Marketing, B2B
Reagan.culbertson@amlan.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c1313a99-b364-4f65-a67e-3ee701e0b88f

New York, NY, Sept. 24, 2026 (GLOBE NEWSWIRE) — Live Oak Acquisition Corp. VI (the “Company”) announced today the closing of its initial public offering of 23,000,000 units, which includes 3,000,000 units issued pursuant to the exercise by the underwriters of their over-allotment option in full. The offering was priced at $10.00 per unit, resulting in gross proceeds of $230,000,000. The Company’s units began trading on September 23, 2026 on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “LOVIU” Each unit consists of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment. Only whole warrants are exercisable. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The warrants will become exercisable 30 days after the completion of the Company’s initial business combination, and will expire five years after the completion of the Company’s initial business combination or earlier upon redemption or its liquidation. Once the securities constituting the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “LOVI” and “LOVIW,” respectively.

Of the proceeds received from the consummation of the initial public offering and a simultaneous private placement of warrants, $230,000,000 (or $10.00 per unit sold in the offering) was placed in a trust account of the Company.

The Company is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company may pursue an acquisition opportunity in any business or industry. The Company’s management team is led by Richard Hendrix, its Chairman, Chief Executive Officer and the co-founder of Live Oak Merchant Partners (“Live Oak”), and Adam Fishman, its President, Chief Financial Officer, Director and a Managing Partner of Live Oak. The Board also includes Ashton Hudson, Andrea Tarbox and Somsak Chivavibul. Gary Wunderlich, Jr. serves as a Senior Advisor.

Santander acted as the sole underwriter for the offering.                                    

The offering was made by means of a prospectus. Copies of the prospectus may be obtained from Santander US Capital Markets LLC, 437 Madison Avenue, New York, NY 10022, Attention: ECM Syndicate, by email at equity-syndicate@santander.us, or by telephone at 833-818-1602. A registration statement relating to the securities was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on September 22, 2026. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed initial public offering and search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all.

Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the “Risk Factors” section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC. Copies of these documents are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investor Contacts

Live Oak Acquisition Corp. VI
4921 William Arnold Road
Memphis, Tennessee 38117
Attn: Adam Fishman
E-mail: IR@liveoakmp.com 

Proceeds to Expand SOL Holdings and Accelerate SOL Per Share Growth

AUSTIN, TX, Sept. 24, 2026 (GLOBE NEWSWIRE) — Forward Industries, Inc. (NASDAQ: FWDI) (the “Company” or “Forward”), the leading Solana treasury company, today announced the closing of its previously announced registered direct offering with an institutional investor. The Company sold 3,125,000 shares of its common stock at a price of $8.00 per share. Forward received gross proceeds of approximately $25 million, before deducting placement agent fees and other offering expenses, and intends to use the net proceeds primarily to acquire additional SOL.

“Forward is growing rapidly, and we are strengthening our financial position as we scale. We secured substantial institutional capital in a single transaction on terms we believe are favorable, without adding ongoing balance sheet obligations. This financing positions us to expand our SOL treasury and increase SOL per share—the measure of growth that matters most to our shareholders. We now have additional capital to extend our competitive lead and pursue opportunities from a position of strength. Our progress reflects disciplined capital allocation and a clear focus on translating treasury growth into lasting shareholder value,” said Ryan Navi, Chief Investment Officer of Forward.

The shares were offered pursuant to the Company’s shelf registration statement on Form S-3ASR (File No. 333-290312), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on September 16, 2025. A prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Electronic copies of the prospectus supplement and the accompanying prospectus may also be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.

A.G.P./Alliance Global Partners acted as sole placement agent for the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Forward Industries, Inc.

Forward Industries, Inc. (NASDAQ: FWDI) is a Solana focused digital asset treasury company, with the strategy to buy, hold, stake, trade, invest in, and grow SOL and SOL related digital assets, protocols and businesses. Forward’s mission is to expand and strengthen the Solana ecosystem by acquiring and staking SOL and engaging with, providing tools to and investing in the Solana network, Solana developers and Solana related projects in order to increase shareholder value. In connection with a private placement transaction in September 2025, Forward launched a digital asset treasury strategy supported by industry leading investors and operating partners including Galaxy Digital and Jump Crypto. For more information on the Company’s Solana treasury strategy, visit www.forwardindustries.com.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. These forward-looking statements address various matters including statements relating to the anticipated use of proceeds from the offering, the expected impact of the offering on SOL per share, the Company’s plan for value creation and strategic advantages, and market size and growth opportunities. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: failure to realize the anticipated benefits of the digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price of Solana and other cryptocurrencies and the incurrence of indebtedness; the risk that the price of the Company’s common stock may be highly correlated to the price of the digital assets that it holds; risks related to the performance and expected return of the companies and projects that the Company has invested in; risks related to increased competition in the industries and markets in which the Company does and will operate (including the applicable digital assets market); risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; as well as those risks and uncertainties identified in the Company’s filings with the SEC. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements. Investors should not place undue reliance on forward-looking statements.

Contacts
Media Contact
comms@forwardindustries.com

Investor Relations Contact
Sean Mansouri, CFA / Aaron D’Souza
Elevate IR
(720) 330-2829
ir@forwardindustries.com

Resort-style amenities enhance vibrant new home community

VENICE, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced the expansive Wellen Park amenity center is now open for residents of its Oakbend Wellen Park community in Venice, Florida. Oakbend Wellen Park is a gated community of new luxury homes by Toll Brothers, and the highly anticipated debut of the exclusive amenities in the Wellen Park master plan marks an exciting milestone for current and future residents.

The newly completed amenity center features a resort-style pool, state-of-the-art fitness center, clubhouse with social lounge, pickleball and bocce courts, a playground, a viewing dock, and walking and biking trails. These thoughtfully curated amenities provide the opportunity for residents to enjoy an active and vibrant lifestyle.

“The highly anticipated opening of this incredible amenity center is an exciting development for our Oakbend Wellen Park community, offering residents a host of resort-style amenities designed to foster relaxation, recreation, and connection,” said Brian O’Hara, Division President of Toll Brothers in Tampa-Sarasota. “This community’s unique blend of luxury homes and premier amenities makes it the perfect choice for home shoppers seeking a relaxed yet elevated lifestyle in the Venice area.”

Oakbend Wellen Park offers one- and two-story single-family home designs ranging from approximately 1,872 to over 3,100 square feet with 3 to 6 bedrooms, 2.5 to 5.5 baths, and 2- to 3-car garages. Homes feature spacious floor plans with options for lofts, flex rooms, and stunning outdoor living spaces. Pricing starts from the upper $400,000s.

Toll Brothers customers will experience one-stop shopping at the Toll Brothers Design Studio. The state-of-the-art Design Studio allows home shoppers to choose from a wide array of selections to personalize their dream home with the assistance of Toll Brothers professional Design Consultants.

Located in the top-rated Sarasota County School District, Oakbend Wellen Park is ideally situated near Florida’s beautiful beaches and offers convenient access to the Downtown Wellen District and CoolToday Park. Residents can enjoy waterfront shopping, dining, and entertainment just minutes from their doorstep.

For more information on Oakbend Wellen Park and Toll Brothers communities throughout Florida, call 855-600-8655 or visit TollBrothers.com/FL.

About Toll Brothers

Toll Brothers, Inc., a Fortune 500 Company, is the nation’s leading builder of luxury homes. The Company was founded in 1967 and became a public company in 1986 with common stock listed on the New York Stock Exchange under the symbol “TOL.” Toll Brothers builds new homes and communities in over 60 markets across the United States, serving first-time, move-up, active-adult, and second-home buyers. The Company also operates its own architectural, engineering, mortgage, title, land development, smart home technology, landscape, and building components manufacturing businesses.

Toll Brothers was named the #1 Most Admired Home Builder in Fortune magazine’s 2026 list of the World’s Most Admired Companies®, the ninth year the Company has achieved this honor. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit TollBrothers.com.

From Fortune, ©2026 Fortune Media IP Limited. All rights reserved. Used under license.

Contact: Andrea Meck | Toll Brothers, Senior Director, Public Relations & Social Media | 215-938-8169 | ameck@tollbrothers.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/83daf748-ad12-4eb6-aa93-caeffd5d294e

https://www.globenewswire.com/NewsRoom/AttachmentNg/8687fe62-483f-4e5f-8704-326b6b840620

https://www.globenewswire.com/NewsRoom/AttachmentNg/e6c5cb4f-358c-4a86-8312-2c681458b88f

Sent by Toll Brothers via Regional Globe Newswire (TOLL-REG)

New luxury community will offer townhomes and single-family homes within the vibrant Cumming City Center district

CUMMING, Ga., Sept. 24, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced Cloverhill at Cumming City Center is coming soon to one of North Georgia’s most sought-after locations, bringing a new collection of luxury townhomes and single-family homes to the heart of Cumming. This new community will feature thoughtfully designed new construction homes within walking distance of Cumming City Center, offering residents an unparalleled blend of convenience, connectivity, and modern living. Site work is underway at 519 Canton Rd in Cumming, and the community is expected to open for sale in spring 2027.

Located near highly regarded Forsyth County schools and just minutes from Highway 20 and GA-400, Cloverhill at Cumming City Center places homeowners close to the area’s premier shopping, dining, recreation, and employment destinations while maintaining a strong sense of neighborhood and community.

The new community will offer three distinctive home collections designed to accommodate a variety of lifestyles and life stages:

• The Alder Collection – Luxury 1,900+ square foot townhomes with sophisticated designs and modern conveniences
• The Juniper Collection – Stylish 2,633+ square foot townhomes featuring versatile layouts and contemporary finishes
• The Wildflower Collection – Spacious 2,319+ square foot detached single-family homes with elevated architecture and flexible living spaces

Prospective homebuyers will have the opportunity to tour two professionally decorated model homes when the community opens this spring, showcasing the exceptional craftsmanship, contemporary interiors, and personalization opportunities available throughout the neighborhood.

“At Cloverhill at Cumming City Center, homeowners will experience a lifestyle where luxury, comfort, and connection come together,” said Eric White, Division President of Toll Brothers in Georgia. “From thoughtfully designed homes and resort-inspired amenities to the walkable access to Cumming City Center’s vibrant mix of shopping, dining, entertainment, and outdoor gathering spaces, this community offers a truly unique opportunity to enjoy the best of Georgia living.”

Residents will enjoy access to a robust amenity package designed to encourage recreation, wellness, and social connection, including a clubhouse, resort-style swimming pool, fitness center, tennis courts, playground, and community gathering spaces.

Beyond the neighborhood, residents will benefit from the energy and excitement of Cumming City Center, where shopping, dining, year-round events, scenic outdoor spaces, and social activities are just steps from home. The community’s premier location also provides convenient access to popular North Georgia destinations, including Lake Lanier and Sawnee Mountain Preserve.

“With its combination of luxury home designs, exceptional amenities, highly regarded schools, and an unbeatable location, Cloverhill at Cumming City Center is poised to become one of Cumming’s most desirable new home communities,” added White.

For more information, contact Toll Brothers at 888-686-5542 or visit TollBrothers.com/GA.

About Toll Brothers
Toll Brothers, Inc., a Fortune 500 Company, is the nation’s leading builder of luxury homes. The Company was founded in 1967 and became a public company in 1986 with common stock listed on the New York Stock Exchange under the symbol “TOL.” Toll Brothers builds new homes and communities in over 60 markets across the United States, serving first-time, move-up, active-adult, and second-home buyers. The Company also operates its own architectural, engineering, mortgage, title, land development, smart home technology, landscape, and building components manufacturing businesses. 

Toll Brothers was named the #1 Most Admired Home Builder in Fortune magazine’s 2026 list of the World’s Most Admired Companies®, the ninth year the Company has achieved this honor. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit TollBrothers.com. 

From Fortune, ©2026 Fortune Media IP Limited. All rights reserved. Used under license.

Contact: Andrea Meck | Toll Brothers, Senior Director, Public Relations & Social Media | 215-938-8169 | ameck@tollbrothers.com

Photos accompanying this announcement are available at: 

https://www.globenewswire.com/NewsRoom/AttachmentNg/843a1d62-195b-4fa1-b54a-c8046bb16ce7

 https://www.globenewswire.com/NewsRoom/AttachmentNg/4ce35da9-c446-46a2-a893-c1882f4f5207

Sent by Toll Brothers via Regional Globe Newswire (TOLL-REG)

Company Announcement

COPENHAGEN, Denmark; September 24, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 13,794 restricted stock units and 13,331 warrants to employees of the Company and the Company’s subsidiaries.

Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,268.

The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted Stock Units. 

The exercise price for each warrant is DKK 2,268. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the fair value of each warrant can be calculated as DKK 781.96.

The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants have been granted on the terms and conditions set out in the warrant program adopted by the Board of Directors on February 23, 2021. Information concerning Genmab’s warrant schemes can be found on www.genmab.com under Investors > Governance > Compensation > Warrants.

About Genmab 
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com or follow us on LinkedIn, X, Facebook and Instagram.

Contact:        
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab^®; the Y-shaped Genmab logo^®; Genmab in combination with the Y-shaped Genmab logo^®; HuMax^®; DuoBody^®; HexaBody^®; DuoHexaBody^®, HexElect^® and KYSO^®.

Company Announcement no. 38
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

Attachment

• 240926_CA38_Warrant and RSU grant